Abstract
Platinum drugs remain an indispensable component of cancer chemotherapy. This study describes the synthesis of two novel platinum(II) complexes (1 and 2) featuring a Michael acceptor, 3-hydroxyacrylic acid, as the leaving group. These complexes were synthesized from cis-diamminediiodo platinum(II) and 3-ethoxyacrylic acid, with structures confirmed via elemental analysis, IR, NMR, and HRMS. In vitro MTT assays demonstrated that both complexes significantly inhibited the growth of human tumor cell lines (HCT-116, A549, CFPAC-1, and BxPC-3), showing comparable IC50 values to oxaliplatin in colorectal and lung cancer models. Furthermore, in vivo studies using a mouse S180 sarcoma model revealed that Complex 1 exhibited superior antitumor activity compared to oxaliplatin. These findings suggest that Complex 1 is a promising candidate for further oncological drug development.
Introduction: The Platinum Paradox
Platinum-based agents such as cisplatin, carboplatin, and oxaliplatin are cornerstones of modern oncology. However, their clinical application is frequently hampered by severe systemic toxicities—including nephrotoxicity and neurotoxicity—and the emergence of drug resistance.
The 'leaving group' of a platinum complex is critical; it detaches to allow the platinum center to coordinate with DNA, the primary target. While most conventional drugs utilize dicarboxylate leaving groups, researchers are exploring novel chemical fragments to improve the therapeutic index. This study investigates the use of a Michael acceptor (3-hydroxyacrylic acid) as a leaving group, hypothesized to enhance anticancer activity through potential covalent interactions with biological targets.
Synthesis and Characterization of Complexes 1 and 2
The researchers synthesized two new complexes, designated 1 and 2, through a multi-step aqueous process. Starting from platinum-iodide precursors, reactive nitrate intermediates were formed and subsequently reacted with sodium 3-ethoxyacrylate to yield 6-membered ring structures.
Structural integrity was verified using Nuclear Magnetic Resonance (NMR), Infrared (IR) spectroscopy, and High-Resolution Mass Spectrometry (HRMS). A key physical difference noted was solubility: Complex 1 demonstrated high water solubility (36.5 mg/mL), whereas Complex 2 was significantly less soluble (1.5 mg/mL). This high solubility makes Complex 1 a more viable candidate for clinical formulation.
Biological Evaluation
In Vitro Cytotoxicity
The antitumor potential was first assessed using MTT assays against four human cancer cell lines: HCT-116 (colorectal), A549 (lung), and two pancreatic lines (CFPAC-1 and BxPC-3). Both complexes showed potent growth inhibition. Specifically, Complex 1 yielded IC50 values of 35.34 μM (HCT-116) and 43.46 μM (A549), performing similarly to the clinical standard, oxaliplatin.
In Vivo Efficacy and Dosing Optimization
Complex 1 was selected for in vivo testing in a mouse S180 sarcoma model. The study highlighted the importance of the dosing schedule. While daily administration proved toxic, a 'bolus' approach—higher doses given at longer intervals—was highly effective. An optimized regimen of 120 mg/kg administered every six days achieved a Tumor Growth Inhibition (TGI) of 66.83%, surpassing the 62.42% TGI observed with oxaliplatin. Crucially, mice on this schedule maintained better body weight, indicating reduced systemic toxicity.
Discussion and Future Directions
The success of Complex 1 is attributed to its unique 6-membered ring structure and the inclusion of a Michael acceptor. This structural motif may alter the kinetics of DNA binding or introduce secondary interactions with cellular proteins.
However, several questions remain. The precise molecular mechanism by which the Michael acceptor influences activity is not yet fully understood. Future research will focus on elucidating these pathways, testing the complexes against a broader array of human tumor xenografts, and expanding the library of Michael-acceptor-based platinum drugs to further refine the structure-activity relationship.
Conclusion
Complex 1 represents a significant step forward in the design of next-generation platinum drugs. With superior in vivo performance and a more favorable safety profile than oxaliplatin in initial models, it warrants further investigation as a potential therapeutic agent for cancer treatment.
Summary updated